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In modern medicine, biomaterials are increasingly used to support or restore 
human body function. Biomaterials can be defined as man-made materials 
designed to interact with living tissue or with a body fluid. Joint prostheses, 
prosthetic heart valves, catheters, and contact lenses can all be considered 
examples of successful applications of biomaterials. 
Biomaterials have led to great improvements in medicine, although usage of these 
materials carries the risk of contracting a biomaterial-associated infection. The 
biomaterial itself then has become the focus of infection. These infections are 
mainly caused by direct contamination during surgery, but they can also be caused 
by haematogenous spread of bacteria from an infection site somewhere else in the 
human body. The clinically important step of bacterial attachment to the surface of 
a biomaterial is then followed by aggregation of other bacteria and growing of the 
bacteria, resulting in biofilm formation. 
In a biofilm, bacteria are embedded in a protective exopolymeric matrix. This 
biofilm mode of growth results in an increased bacterial resistance against 
antimicrobial treatment compared to bacterial resistance of “regular” (planktonic) 
infections. The exact mechanisms resulting in increasing antibiotic resistance of 
bacteria in biofilms are not yet completely understood, although in recent years the 
concept of biofilm is more and more unveiled. Hypotheses include a slow or 
incomplete penetration of the antibiotic into the biofilm, an altered chemical 
microenvironment within the biofilm, and formation of bacterial sub-populations in a 
resistant phenotypic state.42   
The consequences of these biomaterial-associated infections can vary between 
malfunction of the biomaterials implant to lethal sepsis. Although application of 
biomaterials is one of the great improvements in modern medicine, occurrence of a 
biomaterial-associated infection can be considered a serious health problem which 






Biofilms in joint replacement surgery 
Musculoskeletal diseases are the most common causes of severe long-term pain 
and physical disability in people worldwide. Joint diseases account for half of all 
chronic conditions in people aged 60 and over. In people aged over 60 years of 
age some 25% have significant pain and disability from osteoarthritis, and these 
numbers increase for people aged over 65 years of age where osteoarthritis 
already accounts for half of all chronic conditions.51 Osteoarthritis is the most 
important indication for joint prosthesis surgery.  
Demographic developments will increase the impact of these joint diseases for 
society in the near future; the number of people over the age of 50 is expected to 
double between 1990 and 2020. In Europe by 2010, there will be even more 
people over 60 years than people less than 20 years of age. This will result in a 
huge escalation of total treatment costs of joint diseases.51 The above described 
importance of musculoskeletal disease in society was outlined by the United 
Nations by labeling the years 2000 to 2010 as “the Bone and Joint Decade”.  
The most commonly replaced joints are the hip and knee, respectively. In general 
these operations are very successful, both in terms of clinical outcome (high 
improvement in quality of life) as in terms of cost-effectiveness. Nevertheless, 
when biomaterials (polymers, metals or alloys, and ceramics for joint replacement 
surgery) are used, biomaterial-associated infections occur. These biomaterial-
associated infections cause failure of total hip- and knee arthroplasties in 1% to 5% 
of the almost half a million surgeries annually performed worldwide.3,26  
Although the infection percentages can be considered relatively low, the 
consequences for the patient are drastic; most authors recommend the total 
removal of an infected prosthesis in a two-stage revision surgery. These operations 
are accompanied by higher morbidity and reduced joint function. Average costs for 
treatment of an infected joint are estimated between $50,000 and $62,100.2,6,7,41 







Antibiotic-loaded bone cement in joint replacement surgery 
Acrylic bone cements are used for the permanent fixation of joint prostheses, and 
they can also be obtained loaded with antibiotics for the prevention of infection, 
particularly in joint prosthesis revision surgery.25 It is assumed that loading bone 
cement with an antibiotic may decrease the infection rate by local release of 
antibiotic.29,49 Local drug delivery yields higher antibiotic concentrations than can 
be safely achieved with systemic application of antibiotic without systemic side 
effects.48 
Nevertheless, antibiotic release from bone cement is not ideal; antibiotic release 
over time is low, and its release pattern is not very effective in percentage of 
release; on average, only 15% of the antibiotic incorporated in currently applied 
bone cements is released.22,50 Main reason for this is that the most important 
requirement for load-bearing acrylic bone cement is not the efficiency of antibiotic 
release, but maintenance of its mechanical strength.  
Gentamicin-loaded acrylic beads constitute another application used in orthopedics 
and general surgery in which a biomaterial is used as a local drug delivery system 
for the treatment of bone and soft tissue infections. Acrylic beads serve as a non-
load-bearing spacer with a more efficient antibiotic release; gentamicin-loaded 
beads release up to 70% of their antibiotic content within 14 days after 
implantation.48  
Unfortunately, both for beads and bone cements, a sharp drop in release follows 
high initial release; the initial release burst of antibiotic release from bone cement 
occurs in the first 6-10 h.5,20,36 Subsequent release declines sharply, and a slow 
long-term release follows.19,45,47 It was hypothesized that the antibiotic release 
pattern of antibiotic-loaded bone cement is partially a surface phenomenon 
whereas the total amount of antibiotic released depends on bulk porosity.4  
Ideally, gentamicin-loaded beads and bone cements should present a higher total 
release with sustained high concentrations of antibiotic,44 especially because 
aminoglycosides, such as gentamicin, have a concentration dependent 





Research on prevention and treatment of biomaterial-associated infection 
Biomaterial-associated infections pose a threat to future (broader) use of 
biomaterials.40 Both the recognition of the importance of biofilms in biomaterial-
associated infections and the current emergence of bacterial resistance to 
antibiotics has increased this threat.12,24 This has spurred an increased interest in 
physical methods that can affect bacterial adhesion, growth and even disrupt 
established biofilms. Examples of this are studies on positively charged surfaces,15 
on coatings with poly(ethylene oxide) (PEO) brushes,46 on air-bubble induced 
detachment of adhering bacteria,14 on bio-electric,11 bio-magnetic27 and bio-
acoustic31 effects.  
 
Potentials of ultrasound for the treatment of biomaterial-associated infection 
The “bio-acoustic effect”33 refers to application of low-intensity low-frequency 
ultrasound in combination with an antibiotic in order to increase the efficacy of 
antibiotics against biofilm bacteria.39,52  
Ultrasound itself is defined as acoustic energy or sound waves with frequencies 
above 20 kHz (Fig. 1), which is above the audible threshold for humans. It can be 
considered a mechanical wave in which the energy is transmitted by vibrations of 
molecules of the medium through which the wave travels. Ultrasound travels 
predominantly as longitudinal waves, whereas transverse waves are found in bone. 
Its characteristics and nomenclature are further explained in Fig. 1. Ultrasound is 
used in various medical applications, including medical diagnostic imaging and 
physiotherapeutic treatment9 and it is considered to be safe for medical use.17 In 
other studies and applications low-frequency ultrasound has been used to target or 
control drug release28,43 and to allow drugs to cross barriers such as the skin and 
the cornea, which are otherwise nearly impermeable.13,52  
In vitro research showed that ultrasound could enhance antibiotic treatment effect 
both on planktonic bacteria31,37 and biofilm bacteria on polyethylene.21,30,32,33,34,35 





continuous acoustic intensity of 100 mW/cm2 in combination with antibiotics 
showed not to have an additional effect on bacterial viability, whereas an increase 
in acoustic intensity to 300 mW/cm2 decreased bacterial viability, although skin 
lesions were observed. In the following study changing from continuous ultrasound 
to pulsed ultrasound avoided skin lesions, while a decrease in bacterial viability 
was still observed.39 It was suggested that bacteria in biofilm respond to a high 
peak acoustic intensity (pulsed ultrasound) rather than a high average acoustic 
intensity (continuous ultrasound), whereas skin damage correlates with a high 




Figure 1. Representation of a pulsed ultrasound wave. A series of N pulses generates a pulsed 
signal with pulse duration of N times the period (“pulse train”). This period (T) stands for the time 
needed for the wave to travel one wavelength (λ), determined by the chosen frequency (f) of the 
ultrasound signal. Frequency is defined as 1/T, and is given in Hertz (Hz). The difference between 
the peak positive pressure (p+) and the peak negative pressure (p-) is the amplitude (A) of the 
wave; this is important for determining the acoustic intensity (I), (in Watts/cm2), which can be 
considered representative for the mechanical force of the wave. By increasing the ratio of pulse 
duration/pulse repetition (represented by the duty cycle), the energy of the wave per second is 
reduced, thereby reducing heat production, whereas the wave intensity can be maintained or 
increased to high levels by increasing the amplitude and intensity of the wave. A duty cycle of 1:3 
means that one pulse train is followed by 3 identical periods without a pulse.  
 
Exposure of an Escherichia coli biofilm on polyethylene to low-frequency 
ultrasound for 24 h resulted in increased killing of the biofilm in rabbits39, and a 
recent paper showed that extended treatment to 48 h reduced viability to almost 
undetectable levels for E. coli, whereas the Pseudomonas aeruginosa biofilm did 
not decrease by ultrasound.9 The latter was attributed to greater impermeability 














Presumably, ultrasound increases transport of solutes through the biofilm or outer 
bacterial membranes.39 This was in vitro shown for both E. coli and P. aeruginosa, 
and it was concluded that increased antibiotic transport by ultrasound may be 
partially responsible for an increased bacterial killing by ultrasound.8,32 
 
Aim of this thesis 
Ideally, to prevent biofilm infection of implants, a high concentration of an effective 
antibiotic should be achieved around an implant immediately after surgery to 
eradicate planktonic bacteria, present as a result of (inevitable) bacterial 
contamination during surgery.  
Acrylic bone cement and beads have previously been modeled as biomaterials 
consisting of an insoluble matrix with pores and channels in the bulk through which 
gentamicin can elute through diffusion.1,10,22 Nevertheless, antibiotic release is far 
from ideal both in total release as in release pattern in its function of a local drug 
delivery system. Finding ways to increase or accelerate antibiotic release could 
therefore be beneficial. Application of ultrasound in combination with an antibiotic, 
as previously described, resulted in an increased antibiotic efficiency and this could 
possibly be of use in improving prevention and/or treatment of biomaterial-
associated infection in orthopedics.  
The aim of this thesis is to improve the prevention and treatment of infected hip-
and knee arthroplasties by investigating whether antibiotic release by the local drug 
delivery systems used in orthopedics could be improved and whether pulsed 
ultrasound in combination with an antibiotic yields an increased killing of bacterial 
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